Cerapedics Revenue and Competitors
Estimated Revenue & Valuation
- Cerapedics's estimated annual revenue is currently $49.2M per year.
- Cerapedics received $22.0M in venture funding in July 2018.
- Cerapedics's estimated revenue per employee is $193,750
- Cerapedics's total funding is $180.7M.
Employee Data
- Cerapedics has 254 Employees.
- Cerapedics grew their employee count by 15% last year.
Cerapedics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Area VP | Reveal Email/Phone |
3 | Area VP | Reveal Email/Phone |
4 | Area VP | Reveal Email/Phone |
5 | CEO | Reveal Email/Phone |
6 | CEO | Reveal Email/Phone |
7 | General Counsel | Reveal Email/Phone |
8 | VP Strategy, Marketing & Analytics | Reveal Email/Phone |
9 | VP Regulatory | Reveal Email/Phone |
10 | VP Clinical & Market Development | Reveal Email/Phone |
Cerapedics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.6M | 94 | 7% | N/A | N/A |
What Is Cerapedics?
Cerapedics is an advanced orthobiologics company focused on developing its proprietary biomimetic small peptide molecule (P-15) for commercialization in spinal applications. i-FACTOR Peptide Enhanced Bone Graft (P-15/ABM) is only the 2nd FDA PMA Approve bone graft on the market, and it has shown statistical superiority to local autograft through an IDE trial on single-level ACDFs in overall clinical success at one year. i-FACTOR is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action (Attract, Attach, Activate) is designed to support safer and more predictable bone formation compared to other commercially available bone growth factors.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$180.7M
Total Funding
254
Number of Employees
$49.2M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cerapedics News
Cerapedics describes i-FACTOR as a peptide enhanced bone graft that will Attract, Attach, and Activate osteogenic cells to build bone...
WESTMINSTER, Colo., Aug. 17, 2021 /PRNewswire/ -- Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for p ...
WESTMINSTER, Colo., April 29, 2021 /PRNewswire/ -- Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graf ...
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ -- Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. "We are excited to ...
Cerapedics, a private ortho-biologics company, plans an expansion of the company's headquarters located in metro Denver, Colorado.
Other Companies in Westminster
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $68.2M | 255 | 34% | N/A |
#2 | $81.7M | 256 | 15% | N/A |
#3 | $90.7M | 257 | 8% | N/A |
#4 | $35M | 269 | -1% | N/A |
#5 | $35M | 284 | 30% | N/A |
Cerapedics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-04-03 | $15.0M | B | Article | |
| 2012-12-13 | $19.0M | C | MedImmune Ventures, CVF LLC | Article |
| 2014-04-15 | $9.0M | Undisclosed | GE Capital | Article |
| 2015-02-25 | $4.0M | Undisclosed | Article | |
| 2015-04-08 | $8.0M | Undisclosed | GE Capital | Article |
| 2016-09-30 | $11.0M | D | Article | |
| 2017-04-20 | $20.0M | Undisclosed | Oxford Finance | Article |
| 2018-07-16 | $22.0M | Undisclosed | KCK Group | Article |